Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index; none of the 61 sources its claims cite is checked for support yet.
Abstract
Purpose: A systematic literature review was conducted to estimate the global prevalence of Kirsten rat sarcoma virus gene (KRAS) mutations, with an emphasis on the clinically significant KRAS G12C mutation, and to estimate the prognostic significance of these mutations in patients with colorectal cancer (CRC). Design: Relevant English-language publications in the Embase, MEDLINE, and the Cochrane Library databases (from 2009 to 2021) and congress presentations (from 2016 to 2021) were reviewed. Eligible studies were those that reported the prevalence and clinical outcomes of the KRAS G12C mutation in patients with CRC. Results: A total of 137 studies (interventional [n = 8], post hoc analyses of randomized clinical trials [n = 6], observational [n = 122], and longitudinal [n =1]) were reviewed. Sixty-eight studies reported the prevalence of KRAS mutations (KRASm) in 42 810 patients with CRC. The median global prevalence of KRASm was 38% (range, 13.3%-58.9%) and that of the KRAS G12C mutation (KRAS G12C) 3.1% (range, 0.7%-14%). Available evidence suggests that KRASm are possibly more common in tumors that develop on the right side of the colon. Limited evidence suggests a lower objective response rate and inferior disease-free/relapse-free survival in patients with KRAS G12C compared with patients with KRASwt or other KRASm. Conclusion: Our analysis reveals that KRAS G12C is prevalent in 3% of patients with CRC. Available evidence suggests a poor prognosis for patients with KRAS G12C. Right-sided tumors were more likely to harbor KRASm; however, their role in determining clinical outcomes needs to be investigated further.
Overview
CoChat Summary
TL;DR
This systematic literature review of 137 publications estimated a median global prevalence of KRAS G12C of 3.1% (range 0.7%-14%) in colorectal cancer, with KRAS mutations overall at 38% (range 13.3%-58.9%). Limited evidence suggested that KRAS G12C is associated with poorer prognosis, including shorter OS, PFS, and DFS, compared with KRAS wild-type or other KRAS mutations.
Key findings
- In 68 studies reporting prevalence in 42,810 patients with CRC, median global KRASm prevalence was 38% (range 13.3%-58.9%) and median KRAS G12C prevalence was 3.1% (range 0.7%-14%); within KRASm, median KRAS G12C prevalence was 7.7% (range 1.9%-39.7%).
- Regional median KRAS G12C prevalence was 3.8% in Europe (range 1.3%-7.8%), 4.0% in North America (range 0.8%-9.2%), 2.5% in Japan/Asia-Pacific (range 0.7%-14.0%), and 2.9% in the intercontinental region (range 1.0%-11.3%).
- Among 17 publications reporting OS and/or PFS, 11 reported shorter OS/PFS for KRAS G12C than KRASwt or other KRASm; examples included median OS 28.9 vs 36.7 months vs other KRASm and 23 vs 27.1 months (P < .001). ORR was 17.0% for KRAS G12C vs 46.0% for KRAS G12D in one post hoc analysis; 3-year DFS was 61.0% vs 77% for KRASwt (HR 1.66, 95% CI 1.14-2.41; P = .008), and 3-year RFS was 33.3% vs 81.9% (HR 6.57, 95% CI 1.90-17.7; P < .001).
- Five studies noted right-sided colon tumors were more likely to harbor KRASm; evidence on KRAS G12C and tumor sidedness was limited.
Methods
- PRISMA-P/PICO systematic literature review; searched Embase, MEDLINE, Cochrane Library (January 2009-July 2021) and congress abstracts (2016-2021) in two phases.
- Included RCTs, single-arm trials, and observational studies of CRC patients with KRAS G12C; excluded non-English publications, editorials, reviews, animal/in vitro studies, and case reports/case studies. Prevalence data were extracted only when total study population was ≥100 patients or prevalence was the primary aim; clinical outcome data were extracted from all relevant publications.
- 137 publications were selected: 8 interventional (6 single-arm, 2 RCTs), 6 post hoc analyses, 122 observational, 1 longitudinal; 68 studies reported prevalence in 42,810 patients, and 31 publications reported clinical outcomes with KRAS G12C. Quality/risk of bias was assessed with RoB 2 and ROBINS-I.
Limitations
- Stated: prevalence estimates came from studies using a wide variety of techniques, which may have contributed to outlier prevalence; few studies investigated tumor sidedness or compared response rates/duration; KRASm were not routinely assessed, limiting published outcome data; the review was not designed to definitively answer the research questions.
- Stated/evident: heterogeneity in study populations, treatments, and prior lines of therapy made direct comparison of outcomes difficult; small sample sizes and inconsistent findings were noted; no publication reported time to response, depth of response, or treatment discontinuation in KRAS G12C patients.
- Evident: some analyses relied on very few KRAS G12C patients (e.g., 6 patients for a stage II DFS analysis), and prevalence varied widely across geographies and studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
0 Valid · 0 Not valid · 50 Not checked · 63 Own results and interpretations
In the paper
“When a study describing a large outlying prevalence of 14.0% in Indian patients with CRC42 was removed from the analysis, the median prevalence was 2.3% (0.7% to 6.9%).”
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > Geographical Prevalence of KRASm
What the sources say
- Not checked yetcites [42] Veldore, 2014, Prevalence of KRAS mutations in metastatic colorectal cancer: a retrospective observational study from India, Indian J Cancer source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“2.9% in the intercontinental region (range, 1.0% to 11.3%)”
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > Geographical Prevalence of KRASm
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The global median prevalence of KRAS G12C in patients with CRC was 3.1% (range, 0.7% to 14.0%) (Fig. 2A).”
- Also stated in: § Conclusion · plain
“Our analysis reveals that KRAS G12C is prevalent in 3% of patients with CRC.”
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > Geographical Prevalence of KRASm
plainn = 810- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Conclusion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No publication reported on time to response, depth of response, or treatment discontinuation in patients with KRAS G12C.”
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > Clinical outcomes with KRAS mutations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A retrospective review of genomic profiling data from patients with mCRC reported significantly shorter OS for patients with KRAS G12C versus patients with other KRASm (23 vs 27.1 months, P < .001).56”
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > OS and PFS
What the sources say
- Not checked yetcites [56] George, 2020 ( 4050), Prognostic effect of specific RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC), J Clin Oncol source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 113 claims and to verify the 61 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 34
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > OS and PFS
“In a retrospective analysis of data from 404 patients with mCRC who were treated with bevacizumab (80% received bevacizumab as first-line treatment)”
§ Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review > Results > OS and PFS
“| Fiala et al, 201655 | 358 | 9 | Yes | Obs |”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Self-citationPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Cited by
Targeting KRAS: from metabolic regulation to cancer treatment
Shi, Y., Zheng, H., Wang, T., Zhou, S., Zhao, S., Li, M., & Cao, B. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02216-3 · Cited by 89
Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration
Ubaid, S., Kushwaha, R., Kashif, M., & Singh, V. K. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.08.010 · Cited by 85
Prognostic biomarkers: predicting disease outcomes
Sah, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29279-8.00010-7 · Cited by 37
Li, X., Kaboli, P. J., Roozitalab, G., Salahi, S., Qian, H., Zhang, X., Chen, K., & İmani, S. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01199-1 · Cited by 25
Cutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410919 · Cited by 23
Metadata
- Authors
- Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P.
- Affiliations
- Duke Medical Center (US)
- National Cancer Centre Japan (JP)
- Amgen (United States) (US)
- Value Demonstration Practice, Oxford Pharmagenesis , Oxford , UK
- Amgen (Switzerland) (CH)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Modest, Dominik Paul
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-11
- Volume
- 28
- Issue
- 11
- Pages
- e981-e994
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC10628573
- OpenAlex
- W4383872273
- Cited by
- 54
- References
- 83
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 16 · 2023: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Amgen Inc
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- KRAS G12C mutation, KRAS mutation, colorectal cancer, mutation prevalence, prognostic value, right-sided colon tumors, disease-free survival, relapse-free survival, objective response rate, co-occurring mutations
- MeSH terms
- Humans, Lung Neoplasms, Mutation, Neoplasm Recurrence, Local, Colorectal Neoplasms, Prevalence, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. https://app.cochat.ai/papers/10.1093/oncolo/oyad138
- The paper
- Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023). Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review. The Oncologist. https://doi.org/10.1093/oncolo/oyad138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.